Base Therapeutics (shanghai) Co., Ltd.

This early-stage study tests a new treatment called NK510 for people with advanced non-small cell lung cancer (NSCLC) that no longer responds to standard immunotherapy. NK510 are natural killer cells modified to block a protein called TIGIT, which may help them attack cancer more…

This early-phase study tests an experimental cell therapy called NK521 in 18 adults with advanced solid tumors (like liver, stomach, or ovarian cancer) that have not responded to at least two prior treatments and have caused malignant ascites—a painful buildup of fluid in the bel…